GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On January 16, 2024, Willow Biosciences Inc., a leading biotechnology company dedicated to revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announced a collaboration with Enterin, Inc., a clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic disorders, to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients (APIs).
• In December 2023, Ami Organics Limited, a prominent global manufacturer of advanced pharmaceutical intermediates and specialty chemicals, announced that it has signed another definitive agreement with Fermion, a wholly-owned subsidiary of Orion Corporation, a globally operating pharmaceutical company, in Finland. As part of the arrangement, Ami Organics Limited will produce a couple of more advanced pharmaceutical intermediates for Fermion.
• In March 2022, Sumitomo Chemical Co., Ltd., a prominent Japan-based chemical company, announced that it will build a new manufacturing unit for active pharmaceutical ingredients (APIs) and intermediates for small molecule pharmaceuticals at its Oita Works facility. This initiative aims to increase the company's capacity to deliver a wide range of high-quality APIs and intermediates in response to the growing demand for small molecule pharmaceuticals. The new plant is scheduled to come on stream in September 2024.
• In February 2022, CordenPharma, a full-service CDMO, announced the successful acquisition of three production sites from Vifor Pharma, a global specialty pharmaceuticals company. The facilities will be renamed Corden Pharma Fribourg (with its Ettingen office) in Switzerland and Corden Pharma Lisbon in Portugal.